[go: up one dir, main page]

AU2002215004A1 - Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening - Google Patents

Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening

Info

Publication number
AU2002215004A1
AU2002215004A1 AU2002215004A AU1500402A AU2002215004A1 AU 2002215004 A1 AU2002215004 A1 AU 2002215004A1 AU 2002215004 A AU2002215004 A AU 2002215004A AU 1500402 A AU1500402 A AU 1500402A AU 2002215004 A1 AU2002215004 A1 AU 2002215004A1
Authority
AU
Australia
Prior art keywords
vpr
hiv
methods
mitochondrial membrane
membrane permeabilization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215004A
Inventor
Anne-Sophie Belzacq
Catherine Brenner-Jan
Lena Edelmann
Johan Hoebeke
Etienne Daniel Francois Jacotot
Guido Kroemer
Bernard Pierre Roques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Technologie de Compiegne UTC
Institut Pasteur
Original Assignee
Centre National de la Recherche Scientifique CNRS
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Technologie de Compiegne UTC
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Technologie de Compiegne UTC, Institut Pasteur filed Critical Centre National de la Recherche Scientifique CNRS
Publication of AU2002215004A1 publication Critical patent/AU2002215004A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G01N33/5079—Mitochondria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/5432—Liposomes or microcapsules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of Vpr to ANT, mitochondrial membrane permeabilization, and apoptosis are provided.
AU2002215004A 2000-09-11 2001-09-11 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening Abandoned AU2002215004A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23153900P 2000-09-11 2000-09-11
US60/231,539 2000-09-11
US23284100P 2000-09-15 2000-09-15
US60/232,841 2000-09-15
PCT/EP2001/011316 WO2002020570A2 (en) 2000-09-11 2001-09-11 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening

Publications (1)

Publication Number Publication Date
AU2002215004A1 true AU2002215004A1 (en) 2002-03-22

Family

ID=26925199

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215004A Abandoned AU2002215004A1 (en) 2000-09-11 2001-09-11 Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening

Country Status (8)

Country Link
US (3) US7056735B2 (en)
EP (1) EP1370572B1 (en)
JP (1) JP2004508385A (en)
AT (1) ATE415414T1 (en)
AU (1) AU2002215004A1 (en)
CA (1) CA2421872A1 (en)
DE (1) DE60136747D1 (en)
WO (1) WO2002020570A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077826A1 (en) * 2001-02-02 2003-04-24 Lena Edelman Chimeric molecules containing a module able to target specific cells and a module regulating the apoptogenic function of the permeability transition pore complex (PTPC)
FR2827866B1 (en) * 2001-07-27 2004-12-10 Pasteur Institut SYNTHETIC OR NATURAL PEPTIDES BINDING PROTEIN PHOSPHATASE 2A, IDENTIFICATION METHOD AND USES
JP2006248978A (en) * 2005-03-10 2006-09-21 Mebiopharm Co Ltd New liposome preparation
FR2931151A1 (en) * 2008-05-13 2009-11-20 Pharmaleads Soc Par Actions Si NOVEL AMINO ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE
US8968336B2 (en) 2011-12-07 2015-03-03 Edwards Lifesciences Corporation Self-cinching surgical clips and delivery system
CN113289001A (en) * 2020-12-24 2021-08-24 上海市闵行区中心医院 Application of Vpr protein N-terminal amino acid polypeptide for regulating and controlling tumor cell apoptosis in preparation of antitumor drugs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7000898A (en) 1996-11-01 1998-05-29 Emory University Mouse lacking heart-muscle adenine nucleotide translocator protein and methods
AU6053898A (en) 1997-08-04 1999-02-22 Burnham Institute, The A cell-free system of mitochondria-dependent apoptosis, and methods of use ther eof
WO1999007845A1 (en) 1997-08-07 1999-02-18 Smithkline Beecham Laboratories Pharmaceutiques Adenosine nucleotide translocator
EP0911341A1 (en) 1997-10-23 1999-04-28 Smithkline Beecham Laboratoires Pharmaceutiques Adenine nucleotide translocator
CA2349444A1 (en) * 1998-11-03 2000-05-11 Mitokor Production of adenine nucleotide translocator (ant), novel ant ligands and screening assays therefor
CA2359633A1 (en) 1999-01-22 2000-07-27 The Burnham Institute Homing pro-apoptotic conjugates and methods of using same
US6376211B1 (en) * 1999-07-12 2002-04-23 Xoma Technology Ltd. Agents and methods for inhibiting F1/F0 ATPase

Also Published As

Publication number Publication date
US20060052285A1 (en) 2006-03-09
US7642051B2 (en) 2010-01-05
US7056735B2 (en) 2006-06-06
WO2002020570A2 (en) 2002-03-14
ATE415414T1 (en) 2008-12-15
JP2004508385A (en) 2004-03-18
US20020068273A1 (en) 2002-06-06
WO2002020570A3 (en) 2003-10-02
EP1370572B1 (en) 2008-11-26
CA2421872A1 (en) 2002-03-14
DE60136747D1 (en) 2009-01-08
EP1370572A2 (en) 2003-12-17
US20040072146A1 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
ES2066760T3 (en) ALKINYLAMINE NUCLEOTIDES.
NO20020809D0 (en) Isomeric bonded pyrrolocarbazoles and isoindolines
DE60030281D1 (en) METHODS OF IMPROVING THE SENSITIVITY AND SPECIFICITY OF SCREENING PROCEDURES FOR CANCER AND CANCER PREPARATIONS
MXPA03007786A (en) Circular probe amplification (cpa) using energy-transfer primers.
ATE217865T1 (en) COMPOUNDS FOR INHIBITING PHOSPHODIESRERASE IV
MX9803308A (en) Methods and compositions for detection of specific nucleotide sequences.
TR200102191T2 (en) HER-2 / neu fusion proteins.
AU6152301A (en) Detection of nucleic acid hybridization by fluorescence polarization
DE69825066D1 (en) CHANGED PROTEIN KINASES THAT CAN USE MODIFIED NUCLEOTIDE TRIPHOSPHATE SUBSTRATES
DK1187632T3 (en) Treatment with anti-ErbB2 antibodies
DE69128077D1 (en) NUCLEIC ACID AMPLIFICATION WITH DNA-DEPENDENT RNS POLYMERASES ACTIVITY OF RNS REPLICASES
FR2810406B1 (en) NOVEL RARE EARTH CRYPTATES NOT SENSITIVE TO FLUORESCENCE EXTINCTION
AU2002215004A1 (en) Mitochondrial membrane permeabilization bv hiv-1 vpr and methods of screening
EP0924296A3 (en) Methods and means for inducing apoptosis by interference in RNA processing
IL139852A0 (en) Monoclonal antibodies directed against the g3bp protein, and uses
BR9910120A (en) Spisulosin compounds having antitumor activity
TR200102232T2 (en) The process for isolating pseudomonic acid A from the culture medium containing pseudomonic acid complex.
AU2001259131A1 (en) Detection of nucleotide sequence variations via the proofreading activity of polymerases
DK1095032T3 (en) Novel fluorescent CYP2D assay reagents
AU2002210533A1 (en) Identification of cytotoxic activity from the ink of aplysia punctata
ZA965458B (en) Novel detection methods for cryptosporidium
ATE321776T1 (en) PNA CONJUGATE FOR THE THERAPY OF CHRONIC MYELOID LEUKEMIA (CML)
FR2621816B1 (en) ANTIVIRAL APPLICATION OF OLOGONUCLEOTIDES
AU1380899A (en) Immortalized, homozygous stat1-deficient mammalian cell lines and their uses
GB9905580D0 (en) Enyzymatically catalysed signal amplification